Data Exploration and Outcome Prediction Tools

We have introduced new Data Exploration Dashboards, designed to provide an overview of the data at the HARMONY Big Data Platform.

Through these visualization tools clinicians, researchers and statisticians can already explore the feasibility of research using existing data, and fuel new research ideas. Currently available for ALL and AML cohorts, more to follow soon for additional Hematological Malignancies. In addition, we have launched the Outcome Prediction Calculator, a machine-learning model for research purposes only, to help clinicians decide if an AML patient should be considered for allogeneic transplantation.

HARMONY Data Exploration Tools

What can you do with it?

Determine statistical significance to guide the development of your study.

Explore data from ALL and AML cohorts (with more diseases coming soon).

Visualize baseline data to spark new research ideas.

Select specific cohort characteristics to gauge data availability relevant to your research focus.

HARMONY Outcome Prediction Calculator

What can you do with it?

Assess the feasibility of your research projects

The HARMONY BigData Platform is a governed data lake powered by advanced Big Data analytics created to speed up hematology research. It is a best-practice-based data platform where data submitted from various sources – once harmonized and anonymized – create a cohesive data lake ready for scientific research. Beyond a robust technical infrastructure, the Platform offers a secure and trusted research environment compliant with data processing regulations and ethical guidelines. So that researchers can focus on research instead of administrative issues of working on data.

Public-private partnership for Big Data in Hematology

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).